Browse ENPP1

Summary
SymbolENPP1
Nameectonucleotide pyrophosphatase/phosphodiesterase 1
Aliases NPPS; M6S1; PDNP1; ARHR2; COLED; NPP1; E-NPP 1; Ly-41 antigen; alkaline phosphodiesterase 1; membrane compon ......
Chromosomal Location6q22-q23
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Basic function annotation.
> Subcellular Location, Domain and Function
> Gene Ontology
> KEGG and Reactome Pathway
> Subcellular Location, Domain and Function
 
Subcellular Location Cell membrane Single-pass type II membrane protein. Basolateral cell membrane; Single-pass type II membrane protein. Secreted Note=The proteolytically processed form is secreted (By similarity). Targeted to the basolateral membrane in polarized epithelial cells and in hepatocytes, and to matrix vesicles in osteoblasts. In bile duct cells and cancer cells, located to the apical cytoplasmic side.
Domain PF01223 DNA/RNA non-specific endonuclease
PF01663 Type I phosphodiesterase / nucleotide pyrophosphatase
PF01033 Somatomedin B domain
Function

By generating PPi, plays a role in regulating pyrophosphate levels, and functions in bone mineralization and soft tissue calcification. PPi inhibits mineralization by binding to nascent hydroxyapatite (HA) crystals, thereby preventing further growth of these crystals. Preferentially hydrolyzes ATP, but can also hydrolyze other nucleoside 5' triphosphates such as GTP, CTP, TTP and UTP to their corresponding monophosphates with release of pyrophosphate and diadenosine polyphosphates, and also 3',5'-cAMP to AMP. May also be involved in the regulation of the availability of nucleotide sugars in the endoplasmic reticulum and Golgi, and the regulation of purinergic signaling. Appears to modulate insulin sensitivity and function.

> Gene Ontology
 
Biological Process GO:0000271 polysaccharide biosynthetic process
GO:0001503 ossification
GO:0001558 regulation of cell growth
GO:0001933 negative regulation of protein phosphorylation
GO:0005976 polysaccharide metabolic process
GO:0005977 glycogen metabolic process
GO:0005978 glycogen biosynthetic process
GO:0005979 regulation of glycogen biosynthetic process
GO:0005996 monosaccharide metabolic process
GO:0006006 glucose metabolic process
GO:0006073 cellular glucan metabolic process
GO:0006091 generation of precursor metabolites and energy
GO:0006109 regulation of carbohydrate metabolic process
GO:0006112 energy reserve metabolic process
GO:0006766 vitamin metabolic process
GO:0006767 water-soluble vitamin metabolic process
GO:0006771 riboflavin metabolic process
GO:0006790 sulfur compound metabolic process
GO:0006820 anion transport
GO:0006898 receptor-mediated endocytosis
GO:0008286 insulin receptor signaling pathway
GO:0008643 carbohydrate transport
GO:0008645 hexose transport
GO:0009116 nucleoside metabolic process
GO:0009119 ribonucleoside metabolic process
GO:0009141 nucleoside triphosphate metabolic process
GO:0009143 nucleoside triphosphate catabolic process
GO:0009150 purine ribonucleotide metabolic process
GO:0009250 glucan biosynthetic process
GO:0010675 regulation of cellular carbohydrate metabolic process
GO:0010677 negative regulation of cellular carbohydrate metabolic process
GO:0010827 regulation of glucose transport
GO:0010829 negative regulation of glucose transport
GO:0010876 lipid localization
GO:0010906 regulation of glucose metabolic process
GO:0010962 regulation of glucan biosynthetic process
GO:0015698 inorganic anion transport
GO:0015749 monosaccharide transport
GO:0015758 glucose transport
GO:0015980 energy derivation by oxidation of organic compounds
GO:0016049 cell growth
GO:0016051 carbohydrate biosynthetic process
GO:0019318 hexose metabolic process
GO:0019439 aromatic compound catabolic process
GO:0019915 lipid storage
GO:0030002 cellular anion homeostasis
GO:0030278 regulation of ossification
GO:0030282 bone mineralization
GO:0030308 negative regulation of cell growth
GO:0030500 regulation of bone mineralization
GO:0030505 inorganic diphosphate transport
GO:0030643 cellular phosphate ion homeostasis
GO:0030730 sequestering of triglyceride
GO:0031214 biomineral tissue development
GO:0031952 regulation of protein autophosphorylation
GO:0031953 negative regulation of protein autophosphorylation
GO:0032868 response to insulin
GO:0032869 cellular response to insulin stimulus
GO:0032881 regulation of polysaccharide metabolic process
GO:0032885 regulation of polysaccharide biosynthetic process
GO:0033692 cellular polysaccharide biosynthetic process
GO:0033865 nucleoside bisphosphate metabolic process
GO:0033875 ribonucleoside bisphosphate metabolic process
GO:0034032 purine nucleoside bisphosphate metabolic process
GO:0034035 purine ribonucleoside bisphosphate metabolic process
GO:0034637 cellular carbohydrate biosynthetic process
GO:0034655 nucleobase-containing compound catabolic process
GO:0042278 purine nucleoside metabolic process
GO:0042326 negative regulation of phosphorylation
GO:0042726 flavin-containing compound metabolic process
GO:0043255 regulation of carbohydrate biosynthetic process
GO:0043434 response to peptide hormone
GO:0043467 regulation of generation of precursor metabolites and energy
GO:0044042 glucan metabolic process
GO:0044262 cellular carbohydrate metabolic process
GO:0044264 cellular polysaccharide metabolic process
GO:0044270 cellular nitrogen compound catabolic process
GO:0044723 single-organism carbohydrate metabolic process
GO:0045444 fat cell differentiation
GO:0045598 regulation of fat cell differentiation
GO:0045599 negative regulation of fat cell differentiation
GO:0045719 negative regulation of glycogen biosynthetic process
GO:0045912 negative regulation of carbohydrate metabolic process
GO:0045926 negative regulation of growth
GO:0046128 purine ribonucleoside metabolic process
GO:0046323 glucose import
GO:0046324 regulation of glucose import
GO:0046325 negative regulation of glucose import
GO:0046434 organophosphate catabolic process
GO:0046626 regulation of insulin receptor signaling pathway
GO:0046627 negative regulation of insulin receptor signaling pathway
GO:0046700 heterocycle catabolic process
GO:0046777 protein autophosphorylation
GO:0050427 3'-phosphoadenosine 5'-phosphosulfate metabolic process
GO:0051051 negative regulation of transport
GO:0051235 maintenance of location
GO:0055062 phosphate ion homeostasis
GO:0055081 anion homeostasis
GO:0070167 regulation of biomineral tissue development
GO:0070873 regulation of glycogen metabolic process
GO:0070874 negative regulation of glycogen metabolic process
GO:0071375 cellular response to peptide hormone stimulus
GO:0071417 cellular response to organonitrogen compound
GO:0072502 cellular trivalent inorganic anion homeostasis
GO:0072506 trivalent inorganic anion homeostasis
GO:0090305 nucleic acid phosphodiester bond hydrolysis
GO:1900076 regulation of cellular response to insulin stimulus
GO:1900077 negative regulation of cellular response to insulin stimulus
GO:1901292 nucleoside phosphate catabolic process
GO:1901361 organic cyclic compound catabolic process
GO:1901652 response to peptide
GO:1901653 cellular response to peptide
GO:1901657 glycosyl compound metabolic process
Molecular Function GO:0001871 pattern binding
GO:0004518 nuclease activity
GO:0004527 exonuclease activity
GO:0004528 phosphodiesterase I activity
GO:0004551 nucleotide diphosphatase activity
GO:0005044 scavenger receptor activity
GO:0005158 insulin receptor binding
GO:0008081 phosphoric diester hydrolase activity
GO:0030246 carbohydrate binding
GO:0030247 polysaccharide binding
GO:0035529 NADH pyrophosphatase activity
GO:0038024 cargo receptor activity
GO:0042578 phosphoric ester hydrolase activity
GO:0047429 nucleoside-triphosphate diphosphatase activity
GO:0050656 3'-phosphoadenosine 5'-phosphosulfate binding
GO:1901681 sulfur compound binding
Cellular Component GO:0005765 lysosomal membrane
GO:0016323 basolateral plasma membrane
GO:0098852 lytic vacuole membrane
> KEGG and Reactome Pathway
 
KEGG hsa00230 Purine metabolism
hsa00240 Pyrimidine metabolism
hsa00500 Starch and sucrose metabolism
hsa00740 Riboflavin metabolism
hsa00760 Nicotinate and nicotinamide metabolism
hsa00770 Pantothenate and CoA biosynthesis
hsa01100 Metabolic pathways
Reactome R-HSA-1430728: Metabolism
R-HSA-196854: Metabolism of vitamins and cofactors
R-HSA-196849: Metabolism of water-soluble vitamins and cofactors
R-HSA-196843: Vitamin B2 (riboflavin) metabolism
R-HSA-199220: Vitamin B5 (pantothenate) metabolism
Summary
SymbolENPP1
Nameectonucleotide pyrophosphatase/phosphodiesterase 1
Aliases NPPS; M6S1; PDNP1; ARHR2; COLED; NPP1; E-NPP 1; Ly-41 antigen; alkaline phosphodiesterase 1; membrane compon ......
Chromosomal Location6q22-q23
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Literatures that report relations between ENPP1 and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells.
> Text Mining
 

There is no record.
Summary
SymbolENPP1
Nameectonucleotide pyrophosphatase/phosphodiesterase 1
Aliases NPPS; M6S1; PDNP1; ARHR2; COLED; NPP1; E-NPP 1; Ly-41 antigen; alkaline phosphodiesterase 1; membrane compon ......
Chromosomal Location6q22-q23
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets.
> High-throughput Screening
  Statistical results of ENPP1 in screening data sets for detecting immune reponses.
PMID Screening System Cancer Type Cell Line Data Set Statistical Results Relation to immunity
29301958CRISPR-Cas9 melanomaB16F10Pmel-1 T cell NA/NSNA/NS
29301958CRISPR-Cas9 melanomaB16F10OT-1 T cell NA/NSNA/NS
28783722CRISPR-Cas9 melanomaMel6242CT-CRISPR NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX+Anti-PD1 NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX NA/NSNA/NS
25691366RNAiBreast cancerMCF7Luc-CTL assay NA/NSNA/NS
24476824shRNAmelanomaB16Primary screen NA/NSNA/NS
24476824shRNAmelanomaB16Secondary screen NA/NSNA/NS
Summary
SymbolENPP1
Nameectonucleotide pyrophosphatase/phosphodiesterase 1
Aliases NPPS; M6S1; PDNP1; ARHR2; COLED; NPP1; E-NPP 1; Ly-41 antigen; alkaline phosphodiesterase 1; membrane compon ......
Chromosomal Location6q22-q23
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets.
> Expression difference between responders and non-responders
> Mutation difference between responders and non-responders
> Expression difference between responders and non-responders
 
Points in the above scatter plot represent the expression difference of ENPP1 in various data sets.
No PMID Cancer type Group Drug # Res # NRes Log2 (Fold Change) P value Anno
126997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)1412-0.2740.582
226997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)650.0620.948
326997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)87-0.5350.559
428552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 916-0.8520.0296
528552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 59-1.2240.382
628552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 47-0.3870.814
729033130MelanomaallAnti-PD-1 (nivolumab) 26230.120.843
829033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 15110.9280.488
929033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 1112-0.6740.62
1029301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 480.2390.764
1129301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 2001
1229301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 280.7480.472
1329443960Urothelial cancerallAnti-PD-L1 (atezolizumab) 68230-0.460.0312
> Mutation difference between responders and non-responders
 
Points in the above scatter plot represent the mutation difference of ENPP1 in various data sets.
No PMID Cancer type Group Drug # Res # NRes % Mut/Res % Mut/NRes % Diff (R vs NR) Pval Anno
125765070Non-small cell lung cancer (NSCLC)allAnti-PD-1 (pembrolizumab) 14177.107.10.452
225765070Non-small cell lung cancer (NSCLC)smokingAnti-PD-1 (pembrolizumab) 103100101
325765070Non-small cell lung cancer (NSCLC)non-smokingAnti-PD-1 (pembrolizumab) 4140001
426359337MelanomaallAnti-CTLA-4 (ipilimumab) 277305.5-5.50.572
526359337MelanomaBRAFiAnti-CTLA-4 (ipilimumab) 0140001
626359337Melanomanon-BRAFiAnti-CTLA-4 (ipilimumab) 275906.8-6.80.304
726997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)211714.3014.30.238
826997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)860001
926997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)131123.1023.10.223
1028552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 9160001
1128552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 590001
1228552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 470001
1329033130MelanomaallAnti-PD-1 (nivolumab) 38272.602.61
1429033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 22134.504.51
1529033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 16140001
1629301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 11130001
1729301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 610001
1829301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 5120001
Summary
SymbolENPP1
Nameectonucleotide pyrophosphatase/phosphodiesterase 1
Aliases NPPS; M6S1; PDNP1; ARHR2; COLED; NPP1; E-NPP 1; Ly-41 antigen; alkaline phosphodiesterase 1; membrane compon ......
Chromosomal Location6q22-q23
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of ENPP1. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene.
> Lymphocyte
 
Summary
SymbolENPP1
Nameectonucleotide pyrophosphatase/phosphodiesterase 1
Aliases NPPS; M6S1; PDNP1; ARHR2; COLED; NPP1; E-NPP 1; Ly-41 antigen; alkaline phosphodiesterase 1; membrane compon ......
Chromosomal Location6q22-q23
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of ENPP1. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by ENPP1.
> Immunoinhibitor
> Immunostimulator
> MHC molecule
> Immunoinhibitor
 
> Immunostimulator
 
> MHC molecule
 
Summary
SymbolENPP1
Nameectonucleotide pyrophosphatase/phosphodiesterase 1
Aliases NPPS; M6S1; PDNP1; ARHR2; COLED; NPP1; E-NPP 1; Ly-41 antigen; alkaline phosphodiesterase 1; membrane compon ......
Chromosomal Location6q22-q23
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of ENPP1. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene.
> Chemokine
> Receptor
> Chemokine
 
> Receptor
 
Summary
SymbolENPP1
Nameectonucleotide pyrophosphatase/phosphodiesterase 1
Aliases NPPS; M6S1; PDNP1; ARHR2; COLED; NPP1; E-NPP 1; Ly-41 antigen; alkaline phosphodiesterase 1; membrane compon ......
Chromosomal Location6q22-q23
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Distribution of ENPP1 expression across immune and molecular subtypes.
> Immune subtype
> Molecular subtype
> Immune subtype
 
> Molecular subtype
 
Summary
SymbolENPP1
Nameectonucleotide pyrophosphatase/phosphodiesterase 1
Aliases NPPS; M6S1; PDNP1; ARHR2; COLED; NPP1; E-NPP 1; Ly-41 antigen; alkaline phosphodiesterase 1; membrane compon ......
Chromosomal Location6q22-q23
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Associations between ENPP1 and clinical features.
> Overall survival analysis
> Cancer stage
> Tumor grade
> Overall survival
 
> Stage
 
> Grade
 
Summary
SymbolENPP1
Nameectonucleotide pyrophosphatase/phosphodiesterase 1
Aliases NPPS; M6S1; PDNP1; ARHR2; COLED; NPP1; E-NPP 1; Ly-41 antigen; alkaline phosphodiesterase 1; membrane compon ......
Chromosomal Location6q22-q23
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Drugs targeting ENPP1 collected from DrugBank database.
> Drugs from DrugBank database
 

  Details on drugs targeting ENPP1.
ID Name Drug Type Targets #Targets
DB00811RibavirinSmall MoleculeADK, ENPP1, IMPDH1, IMPDH2, NT5C25
DB01143AmifostineSmall MoleculeALPPL2, ENPP12
DB06408TaribavirinSmall MoleculeENPP1, IMPDH1, NT5C23
DB11077Polyethylene glycol 400Small MoleculeENPP11